Markus Maulhardt

Dr. Markus Maulhardt

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 February 2026 in npj Digital Medicine
Verified
Journal Article
Open access
PDF file
FSF. Schwarz
F. Schwarz
LLL. Levien
L. Levien
MMMarkus Maulhardt
Markus Maulhardt
GWG. Wulf
G. Wulf
NBN. Brökers
N. Brökers
EAEnver Aydilek
Enver Aydilek
Autologous stem-cell transplantation is a fundamental therapy for multiple myeloma. Although inpatient chemo-based stem-cell mobilization (SCM) is standard care in Germany, outpatient approaches could ease healthcare constraints. We analyzed 109 myeloma patients undergoing SCM and collection at the University Medical Center Göttingen for safety. We then trained machine learning models to predict adverse events (AEs) requiring hospitalization and to forecast AE onset timing for optimized ward management. In our cohort, 97% achieved successful collection, but 69% experienced severe AEs necessitating hospitalization. Simulations suggest a risk-stratified outpatient protocol could cut bed usage by at least one third without compromising safety. Classification models accurately predicted some AE types (e.g., elevated creatinine, ROC-AUC 1.0), though neutropenic fever remained challenging (ROC-AUC 0.67). Regression models forecast AE onset with a mean error of just over one day. These results outline a data-driven roadmap for safely adopting outpatient SCM and optimizing resource allocation in clinical practice.

18 August 2025 in HemaSphere
Verified
Journal Article
Open access
MMMarkus Maulhardt
Markus Maulhardt
SCSimon Call
Simon Call
HBHristo Boyadzhiev
Hristo Boyadzhiev
AAAnca Maria Albici
Anca Maria Albici
KHKeven Hörster
Keven Hörster
ESEvgenii Shumilov
Evgenii Shumilov

3 June 2026 in Blood Advances
Verified
Journal Article
Open access
VZVanja Zeremski
Vanja Zeremski
SBSina Alexandra Beer
Sina Alexandra Beer
FDFrederik Damm
Frederik Damm
MFMareike Frick
Mareike Frick
THTobias Ronny Haage
Tobias Ronny Haage
DMDimitrios Mougiakakos
Dimitrios Mougiakakos

30 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
MMMarkus Maulhardt
Markus Maulhardt
LKLina Jenny Kolloch
Lina Jenny Kolloch
GWGina Westhofen
Gina Westhofen
EAEnver Aydilek
Enver Aydilek
MLMargarete Elisabeth Laage
Margarete Elisabeth Laage
GWGerald Wulf
Gerald Wulf
Background: Large B-cell lymphoma (LBCL) remains challenging in the relapsed/refractory (r/r) setting. CD19-directed chimeric antigen receptor (CAR) T-cell therapy has become the preferred cellular immunotherapy, whereas allogeneic hematopoietic cell transplantation (allo-HCT) remains a salvage option. Comparative real-world data are limited.Patients and Methods: We retrospectively analyzed 187 patients with r/r LBCL treated with either allo-HCT or axicabtagene ciloleucel (axi-cel) at a single center. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints included relapse incidence (RI), non-relapse mortality (NRM), and treatment-related toxicities. Propensity score matching (PSM) was performed to adjust for baseline differences.Results: Response rates and RI were comparable between groups. However, NRM was significantly higher after allo-HCT than after axi-cel (36% vs. 12%; p<0.001), mainly due to infections and graft-versus-host disease. Consequently, axi-cel was associated with superior 12-month PFS (50.1% vs. 33.8%) and OS (60.5% vs. 43.2%; both p<0.05). These findings were confirmed in third-line-or-later and PSM analyses. Primary refractoriness and poor performance status independently predicted inferior outcomes. In patients with chemorefractory disease before cellular therapy, axi-cel provided significantly improved survival, whereas outcomes were comparable in patients with chemosensitive disease.Conclusion: Axi-cel provided superior survival compared with allo-HCT in r/r LBCL, primarily owing to lower treatment-related mortality and improved disease control in patients with chemorefractory disease.

27 February 2026 in In Vivo
Verified
Journal Article
Open access
MMMarkus Maulhardt
Markus Maulhardt
AAAlexander C. Angleitner
Alexander C. Angleitner
RARehsan Akdas
Rehsan Akdas
WHWilken Harms
Wilken Harms
PSPatricia Scharfenberg
Patricia Scharfenberg
JBJudith Buentzel
Judith Buentzel
Geotrichosis caused by Geotrichum candidum (G. candidum) is a rarely reported opportunistic infection. Immunocompromised hosts are particularly susceptible to this fungal strain. To shed more light on this opportunistic pathogen and its significance in human disease, we analyzed publicly available data and discussed potential therapies for this fungal strain. A systematic online search was conducted, and suitable case reports were retrieved for subsequent retrospective analysis. We eventually selected data on 22 cases for final analysis according to the PRISMA guidelines. To summarize the demographic and clinical variables, descriptive statistical measures were applied. Besides, we contributed one additional case of a leukemia patient with catastrophic G. candidum sepsis from our institution to the data pool. G. candidum mycosis is frequently deadly for patients with cancer. Leukopenia contributes to higher mortality rates in this vulnerable population. Cancer itself as well as hematological malignancies are more common among non-survivors in this explorative analysis [patients with cancer (n=11) vs. others (n=12), p<0.01; blood cancer (n=8) vs. others (n=15), p<0.05]. We did not detect a consistent association regarding differences in the choice of antifungal compounds for treatment (e.g., amphotericin B/liposomal amphotericin B vs. others) or whether monotherapy or sequential therapy was administered. One patient with acute myeloid leukemia from our center eventually died due to a mixed fungal pneumonia including G. candidum despite broad antifungal treatment. Although deemed a yeast of low virulence, G. candidum can turn into a deadly germ for immunocompromised hosts. Leukopenia probably aggravates the course of the disease in these patients.

14 November 2026 in Blood Advances
Verified
Journal Article
Closed access
ESEvgenii Shumilov
Evgenii Shumilov
LKLina Kolloch
Lina Kolloch
PFPhilipp Faustmann
Philipp Faustmann
DUDébora-Michèle Grote Urtubey
Débora-Michèle Grote Urtubey
MTMarcel Teichert
Marcel Teichert
GLGeorg Lenz
Georg Lenz
Few treatment options remain for patients with large B-cell lymphoma progressing after multiple lines of therapy, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German centers. Ninety-three heavily pretreated patients received lonca in the third and later lines of therapy. Seventy-six percent had received treatment with chimeric antigen receptor T cells (n = 55), bispecific antibodies (n = 56), or both (n = 40). The overall response rate was 27%, and complete response rate was 10%. Median progression-free survival (mPFS) and median overall survival (mOS) were 2.2 and 4.4 months, respectively. The mPFS of responders was 11.4 months. Toxicity was acceptable, with grade ≥3 infections (in 13% of patients) being the most common adverse event. Patients receiving subsequent allogeneic stem cell transplantation survived significantly longer than the remaining nonconsolidated patients (mOS: 15.2 vs 3.8 months; P = .048). In multivariable analysis, no response to the last therapy before lonca (OS: hazard ratio [HR], 2.5; P = .014) and secondary International Prognostic Index (PFS/OS: HR, ≥2.0; P ≤ .024) were significantly associated with poor outcomes. Lonca demonstrated a favorable safety profile with moderate efficacy in heavily pretreated patients. Along with enabling timely access to subsequent therapy, efficacy in earlier lines with combination partners may further increase response rates and durability of response.